Publications
Filters: First Letter Of Keyword is P [Clear All Filters]
Statistical issues and advances in cancer precision medicine research." J Biopharm Stat 28, no. 2 (2018): 215-216.
"A penalized likelihood approach for investigating gene-drug interactions in pharmacogenetic studies." Biometrics 71, no. 2 (2015): 529-37.
"Assessing Combinability of Phylogenomic Data Using Bayes Factors." Syst Biol 68, no. 5 (2019): 744-754.
"Estimating individualized treatment regimes from crossover designs." Biometrics 76, no. 3 (2020): 778-788.
"A regularized variable selection procedure in additive hazards model with stratified case-cohort design." Lifetime Data Anal 24, no. 3 (2018): 443-463.
"Time course and prognostic value of serum GFAP, pNFH, and S100β concentrations in dogs with complete spinal cord injury because of intervertebral disc extrusion." J Vet Intern Med 33, no. 2 (2019): 726-734.
"Time course and prognostic value of serum GFAP, pNFH, and S100β concentrations in dogs with complete spinal cord injury because of intervertebral disc extrusion." J Vet Intern Med 33, no. 2 (2019): 726-734.
"Time course and prognostic value of serum GFAP, pNFH, and S100β concentrations in dogs with complete spinal cord injury because of intervertebral disc extrusion." J Vet Intern Med 33, no. 2 (2019): 726-734.
"Time course and prognostic value of serum GFAP, pNFH, and S100β concentrations in dogs with complete spinal cord injury because of intervertebral disc extrusion." J Vet Intern Med 33, no. 2 (2019): 726-734.
"Statistical considerations for analysis of microarray experiments." Clin Transl Sci 4, no. 6 (2011): 466-77.
"Power and sample size calculations for SNP association studies with censored time-to-event outcomes." Genet Epidemiol 36, no. 6 (2012): 538-48.
"Statistical considerations for analysis of microarray experiments." Clin Transl Sci 4, no. 6 (2011): 466-77.
"Power and sample size calculations for SNP association studies with censored time-to-event outcomes." Genet Epidemiol 36, no. 6 (2012): 538-48.
"Latent class model characterization of neighborhood socioeconomic status." Cancer Causes Control 27, no. 3 (2016): 445-52.
"Secondary outcome analysis for data from an outcome-dependent sampling design." Stat Med 37, no. 15 (2018): 2321-2337.
"Secondary outcome analysis for data from an outcome-dependent sampling design." Stat Med 37, no. 15 (2018): 2321-2337.
"Enrollment Trends and Disparity Among Patients With Lung Cancer in National Clinical Trials, 1990 to 2012." J Clin Oncol 34, no. 33 (2016): 3992-3999.
"Gene selection using iterative feature elimination random forests for survival outcomes." IEEE/ACM Trans Comput Biol Bioinform 9, no. 5 (2012): 1422-31.
"Analysing breast cancer microarrays from African Americans using shrinkage-based discriminant analysis." Hum Genomics 5, no. 1 (2010): 5-16.
"Pathway-based identification of SNPs predictive of survival." Eur J Hum Genet 19, no. 6 (2011): 704-9.
"Sample size considerations of prediction-validation methods in high-dimensional data for survival outcomes." Genet Epidemiol 37, no. 3 (2013): 276-82.
"Statistical aspect of translational and correlative studies in clinical trials." Chin Clin Oncol 5, no. 1 (2016): 11.
"Pathway-based identification of SNPs predictive of survival." Eur J Hum Genet 19, no. 6 (2011): 704-9.
"Comparing oncology clinical programs by use of innovative designs and expected net present value optimization: Which adaptive approach leads to the best result?" J Biopharm Stat 27, no. 3 (2017): 457-476.
"Static and Dynamic DNA Loops form AP-1-Bound Activation Hubs during Macrophage Development." Mol Cell 67, no. 6 (2017): 1037-1048.e6.
"Static and Dynamic DNA Loops form AP-1-Bound Activation Hubs during Macrophage Development." Mol Cell 67, no. 6 (2017): 1037-1048.e6.
"Intergenerational response to the endocrine disruptor vinclozolin is influenced by maternal genotype and crossing scheme." Reprod Toxicol 78 (2018): 9-19.
"Intergenerational response to the endocrine disruptor vinclozolin is influenced by maternal genotype and crossing scheme." Reprod Toxicol 78 (2018): 9-19.
"Intergenerational response to the endocrine disruptor vinclozolin is influenced by maternal genotype and crossing scheme." Reprod Toxicol 78 (2018): 9-19.
"Purity Independent Subtyping of Tumors (PurIST), A Clinically Robust, Single-sample Classifier for Tumor Subtyping in Pancreatic Cancer." Clin Cancer Res 26, no. 1 (2020): 82-92.
"Ascertainment, classification, and impact of neoplasm detection during prolonged treatment with dual antiplatelet therapy with prasugrel vs. clopidogrel following acute coronary syndrome." Eur Heart J 37, no. 4 (2016): 412-22.
"Ascertainment, classification, and impact of neoplasm detection during prolonged treatment with dual antiplatelet therapy with prasugrel vs. clopidogrel following acute coronary syndrome." Eur Heart J 37, no. 4 (2016): 412-22.
"Application of a sequential multiple assignment randomized trial (SMART) design in older patients with chronic lymphocytic leukemia." Ann Oncol 30, no. 4 (2019): 542-550.
"Ten-year experience with extended criteria cardiac transplantation." Circ Heart Fail 6, no. 6 (2013): 1230-8.
"Ten-year experience with extended criteria cardiac transplantation." Circ Heart Fail 6, no. 6 (2013): 1230-8.
"Comparative effectiveness of oxaliplatin vs non-oxaliplatin-containing adjuvant chemotherapy for stage III colon cancer." J Natl Cancer Inst 104, no. 3 (2012): 211-27.
""Genome-wide association study identifies five new schizophrenia loci." Nat Genet 43, no. 10 (2011): 969-76.
Predictive Blood-Based Biomarkers in Patients with Epithelial Ovarian Cancer Treated with Carboplatin and Paclitaxel with or without Bevacizumab: Results from GOG-0218." Clin Cancer Res 26, no. 6 (2020): 1288-1296.
"Probability-enhanced sufficient dimension reduction for binary classification." Biometrics 70, no. 3 (2014): 546-55.
"Multiscale adaptive marginal analysis of longitudinal neuroimaging data with time-varying covariates." Biometrics 68, no. 4 (2012): 1083-92.
"Sex differences in grey matter atrophy patterns among AD and aMCI patients: results from ADNI." Neuroimage 56, no. 3 (2011): 890-906.
"A junction coverage compatibility score to quantify the reliability of transcript abundance estimates and annotation catalogs." Life Sci Alliance 2, no. 1 (2019).
"The association between copy number aberration, DNA methylation and gene expression in tumor samples." Nucleic Acids Res 46, no. 6 (2018): 3009-3018.
"Estimation of a partially linear additive model for data from an outcome-dependent sampling design with a continuous outcome." Biostatistics 17, no. 4 (2016): 663-76.
"Estimation of a partially linear additive model for data from an outcome-dependent sampling design with a continuous outcome." Biostatistics 17, no. 4 (2016): 663-76.
"Meta-analysis of sequencing studies with heterogeneous genetic associations." Genet Epidemiol 38, no. 5 (2014): 389-401.
"A global sensitivity test for evaluating statistical hypotheses with nonidentifiable models." Biometrics 66, no. 2 (2010): 558-66.
"A global sensitivity test for evaluating statistical hypotheses with nonidentifiable models." Biometrics 66, no. 2 (2010): 558-66.
"A New Method for Detecting Associations with Rare Copy-Number Variants." PLoS Genet 11, no. 10 (2015): e1005403.
"Integrative pipeline for profiling DNA copy number and inferring tumor phylogeny." Bioinformatics 34, no. 12 (2018): 2126-2128.
"Survival Benefit of Lung Transplantation in the Modern Era of Lung Allocation." Ann Am Thorac Soc 14, no. 2 (2017): 172-181.
"Validation of survival prognostic models for non-small-cell lung cancer in stage- and age-specific groups." Lung Cancer 90, no. 2 (2015): 281-7.
"Onset of persistent pseudomonas aeruginosa infection in children with cystic fibrosis with interval censored data." BMC Med Res Methodol 16, no. 1 (2016): 122.
"On Enrichment Strategies for Biomarker Stratified Clinical Trials." J Biopharm Stat 28, no. 2 (2018): 292-308.
"Analysis of gene-gene interactions using gene-trait similarity regression." Hum Hered 78, no. 1 (2014): 17-26.
"ROC curve estimation under test-result-dependent sampling." Biostatistics 14, no. 1 (2013): 160-72.
"Auxiliary variable-enriched biomarker-stratified design." Stat Med 37, no. 30 (2018): 4610-4635.
"SCOPE: A Normalization and Copy-Number Estimation Method for Single-Cell DNA Sequencing." Cell Syst 10, no. 5 (2020): 445-452.e6.
"Pathway-guided identification of gene-gene interactions." Ann Hum Genet 78, no. 6 (2014): 478-91.
"Analysis of gene-gene interactions using gene-trait similarity regression." Hum Hered 78, no. 1 (2014): 17-26.
"Risk calculators are useful but..." J Thorac Cardiovasc Surg 151, no. 3 (2016): 706-707.
"Pathway-guided identification of gene-gene interactions." Ann Hum Genet 78, no. 6 (2014): 478-91.
"Onset of persistent pseudomonas aeruginosa infection in children with cystic fibrosis with interval censored data." BMC Med Res Methodol 16, no. 1 (2016): 122.
"Reexamining Dis/Similarity-Based Tests for Rare-Variant Association with Case-Control Samples." Genetics 209, no. 1 (2018): 105-113.
"Onset of persistent pseudomonas aeruginosa infection in children with cystic fibrosis with interval censored data." BMC Med Res Methodol 16, no. 1 (2016): 122.
"Module-based association analysis for omics data with network structure." PLoS One 10, no. 3 (2015): e0122309.
"On Enrichment Strategies for Biomarker Stratified Clinical Trials." J Biopharm Stat 28, no. 2 (2018): 292-308.
"Identifying individual risk rare variants using protein structure guided local tests (POINT)." PLoS Comput Biol 15, no. 2 (2019): e1006722.
"Identifying individual risk rare variants using protein structure guided local tests (POINT)." PLoS Comput Biol 15, no. 2 (2019): e1006722.
"Systematic review and network meta-analysis comparing palbociclib with chemotherapy agents for the treatment of postmenopausal women with HR-positive and HER2-negative advanced/metastatic breast cancer." Breast Cancer Res Treat 166, no. 1 (2017): 167-177.
"Systematic review and network meta-analysis comparing palbociclib with chemotherapy agents for the treatment of postmenopausal women with HR-positive and HER2-negative advanced/metastatic breast cancer." Breast Cancer Res Treat 166, no. 1 (2017): 167-177.
"Systematic review and network meta-analysis comparing palbociclib with chemotherapy agents for the treatment of postmenopausal women with HR-positive and HER2-negative advanced/metastatic breast cancer." Breast Cancer Res Treat 166, no. 1 (2017): 167-177.
"Single cell analysis reveals distinct immune landscapes in transplant and primary sarcomas that determine response or resistance to immunotherapy." Nat Commun 11, no. 1 (2020): 6410.
"I-Boost: an integrative boosting approach for predicting survival time with multiple genomics platforms." Genome Biol 20, no. 1 (2019): 52.
"A new Bayesian joint model for longitudinal count data with many zeros, intermittent missingness, and dropout with applications to HIV prevention trials." Stat Med 38, no. 30 (2019): 5565-5586.
"A new Bayesian joint model for longitudinal count data with many zeros, intermittent missingness, and dropout with applications to HIV prevention trials." Stat Med 38, no. 30 (2019): 5565-5586.
"Semiparametric sieve maximum likelihood estimation under cure model with partly interval censored and left truncated data for application to spontaneous abortion." Lifetime Data Anal 25, no. 3 (2019): 507-528.
"Robust regression for optimal individualized treatment rules." Stat Med 38, no. 11 (2019): 2059-2073.
"Radiomics analysis using stability selection supervised component analysis for right-censored survival data." Comput Biol Med 124 (2020): 103959.
"Reporting and Guidelines in Propensity Score Analysis: A Systematic Review of Cancer and Cancer Surgical Studies." J Natl Cancer Inst 109, no. 8 (2017).
"Reporting and Guidelines in Propensity Score Analysis: A Systematic Review of Cancer and Cancer Surgical Studies." J Natl Cancer Inst 109, no. 8 (2017).
"A longitudinal functional analysis framework for analysis of white matter tract statistics." Inf Process Med Imaging 23 (2013): 220-31.
"Seamless Phase IIa/IIb and enhanced dose-finding adaptive design." J Biopharm Stat 26, no. 5 (2016): 912-23.
"Assessing model fit in joint models of longitudinal and survival data with applications to cancer clinical trials." Stat Med 33, no. 27 (2014): 4715-33.
"Using decision lists to construct interpretable and parsimonious treatment regimes." Biometrics 71, no. 4 (2015): 895-904.
"TEAM: efficient two-locus epistasis tests in human genome-wide association study." Bioinformatics 26, no. 12 (2010): i217-27.
"Bayesian gamma frailty models for survival data with semi-competing risks and treatment switching." Lifetime Data Anal 20, no. 1 (2014): 76-105.
"Rapid and robust resampling-based multiple-testing correction with application in a genome-wide expression quantitative trait loci study." Genetics 190, no. 4 (2012): 1511-20.
"Inference on treatment effects from a randomized clinical trial in the presence of premature treatment discontinuation: the SYNERGY trial." Biostatistics 12, no. 2 (2011): 258-69.
"Rapid and robust resampling-based multiple-testing correction with application in a genome-wide expression quantitative trait loci study." Genetics 190, no. 4 (2012): 1511-20.
"Inference on treatment effects from a randomized clinical trial in the presence of premature treatment discontinuation: the SYNERGY trial." Biostatistics 12, no. 2 (2011): 258-69.
"A robust method for estimating optimal treatment regimes." Biometrics 68, no. 4 (2012): 1010-8.
"Assessing model fit in joint models of longitudinal and survival data with applications to cancer clinical trials." Stat Med 33, no. 27 (2014): 4715-33.
"Sensitivity analysis for missing outcomes in time-to-event data with covariate adjustment." J Biopharm Stat 26, no. 2 (2016): 269-79.
"Reinforcement learning strategies for clinical trials in nonsmall cell lung cancer." Biometrics 67, no. 4 (2011): 1422-33.
"Assessing gene-environment interactions for common and rare variants with binary traits using gene-trait similarity regression." Genetics 199, no. 3 (2015): 695-710.
"Hypothesis testing at the extremes: fast and robust association for high-throughput data." Biostatistics 16, no. 3 (2015): 611-25.
"Analysis of secondary phenotypes in multigroup association studies." Biometrics 76, no. 2 (2020): 606-618.
"Semiparametric inference for a 2-stage outcome-auxiliary-dependent sampling design with continuous outcome." Biostatistics 12, no. 3 (2011): 521-34.
"A varying-coefficient generalized odds rate model with time-varying exposure: An application to fitness and cardiovascular disease mortality." Biometrics 75, no. 3 (2019): 853-863.
"